Lightbeam Health Solutions Announces Partnership with Genetic Testing Company, Ambry Genetics
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Today, only a fraction of individuals with a hereditary predisposition to disease are tested," said Rob Guigley, Chief Commercial Officer, Ambry Genetics. "Our partnership with Lightbeam intends to bring greater access to the community and empower patients and providers to make informed preventative decisions that can improve health care and management. The potential impact of this relationship is significant for patients, providers, and payors."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
IRVING, Texas -- Businesswire -- Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, is proud to announce their partnership with Ambry Genetics, a Konica Minolta Precision Medicine (KMPM) company. The partnership provides precision genetic testing data within the Lightbeam application to help organizations predict increased risk for common cancers and chronic conditions within patient populations.
According to the Centers for Disease Control and Prevention, 1.6 million people are diagnosed with cancer each year in the United States. The Ambry Genetics-Lightbeam partnership is expected to reduce this burden with tools for early detection and prevention by allowing providers to quickly identify, assess, and engage patients who meet specific risk factors. As the body of genetic evidence expands, so too will the value brought to mutual clients of Lightbeam and Ambry Genetics.
The CARE (Comprehensive, Assessment, Risk and Education) Program™ will integrate into the Lightbeam Platform, providing an additional clinical data stream for clients to enhance Lightbeam’s proprietary Ability-to-Impact (ATI) risk score. Genetic risk information is critical because it informs personalized patient care to include preventive surgeries, increased cancer screening, and in some cases, targeted therapies.
“At Lightbeam, part of our vision is to help organizations transform care delivery from being reactive to proactive,” said Pat Cline, CEO of Lightbeam. “We believe this partnership with Ambry Genetics will positively impact lives with its ability to indicate whether a person is high-risk for cancer or other diseases. In combination with our industry-leading analytics platform, Ambry’s genetic data further enhances how Lightbeam clients can improve quality, reduce costs, and positively impact outcomes for the populations they serve.”
“Today, only a fraction of individuals with a hereditary predisposition to disease are tested,” said Rob Guigley, Chief Commercial Officer, Ambry Genetics. “Our partnership with Lightbeam intends to bring greater access to the community and empower patients and providers to make informed preventative decisions that can improve health care and management. The potential impact of this relationship is significant for patients, providers, and payors.”
For more information on this innovative partnership, visit the Lightbeam Health booth, #2060 in the Sands Expo, at HIMSS21 in Las Vegas, Nevada, from August 9-13, 2021.
About AMBRY GENETICS ®
Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions.
About Lightbeam Health Solutions
Lightbeam Health Solutions delivers a revolutionary model for managing patient populations and associated risk. Lightbeam’s vision is to bring health data into the light through the use of analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Lightbeam’s platform facilitates end-to-end population health management for ACOs, payers, provider groups, health systems, and other healthcare organizations aspiring to provide superior care at a lower cost. For more information, visit www.lightbeamhealth.com, and follow Lightbeam on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005688/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Lightbeam Health Solutions
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 대한암협회, 2024년 유방암 의식 향상 핑크리본 캠페인 성황리 마무리 - 뉴스와이어
- 아리랑TV, 외국인을 위한 힐링콘서트 ‘PLAY with K’ 개최 - 뉴스와이어
- 현대자동차, 제3회 ‘수소의 날’ 기념 수소전기차 콘셉트카 전시 - 뉴스와이어
- 빛과 소리의 어우러짐 ‘컬러풀 랩소디’ 11월 10일 공연 - 뉴스와이어
- 경콘진, 프랑스 칸 ‘MIPCOM 2024’에서 K-콘텐츠 세션 최초 개최 - 뉴스와이어
- 이아이피그리드, 전력 수요관리사업자 인수 통한 ‘VPP+EaaS’ 비즈니스 개시 - 뉴스와이어
- 엑소스템텍 ‘엑소좀 의약품 사전 충진형 니들프리 주사기기’ 개발 국책과제 선정 - 뉴스와이
- 동아ST, 2024년 3분기 실적 요약 - 뉴스와이어
- 제10회 EUNIC x EU 영화제, 서울역사박물관에서 개최 - 뉴스와이어
- 한국 딜로이트 그룹 ‘CFO를 위한 지속가능성 공시 가이드’ 리포트 시리즈 발행 - 뉴스와이어